Immunotherapy in Inflammatory Bowel Disease

被引：27

作者：

Ahluwalia, Jatinder P. ^{[1
,2
,3
]}

机构：

[1] Gastroenterol Clin Acadiana, Lafayette, LA USA

[2] Lafayette Gen Med Ctr, Lafayette, LA USA

[3] Tulane Univ, Dept Med, New Orleans, LA 70118 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 2012年 / 96卷 / 03期

关键词：

Crohn disease; Ulcerative colitis; Anti-tumor necrosis factor-alpha; Infliximab; Adalimumab; Certolizumab; Anti-alpha(4)-integrin therapy; Natalizumab; Biologics; NECROSIS-FACTOR-ALPHA; ADALIMUMAB INDUCTION THERAPY; CERTOLIZUMAB PEGOL CDP870; ACTIVE CROHNS-DISEASE; C-REACTIVE PROTEIN; LONG-TERM EFFICACY; MONOCLONAL-ANTIBODY; ULCERATIVE-COLITIS; MAINTENANCE THERAPY; CORTICOSTEROID-THERAPY;

D O I：

10.1016/j.mcna.2012.04.009

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Inflammatory bowel disease affects an increasing number of patients worldwide and is associated with significant morbidity. The dysregulation of the immune system with increased expression of proinflammatory cytokines and increased mucosal expression of vascular adhesion molecules play an important role in its pathogenesis. Strategies targeting TNF-alpha and alpha4-integrin have led to the development of novel therapies for treatment of patients with IBD. This article discusses the efficacy of immunologic agents currently approved for treating Crohn disease and ulcerative colitis and reviews the risks and challenges associated with their use.

引用

页码：525 / +

页数：21

共 95 条

[1]

Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab [J].

Afif, Waqqas ;

Leighton, Jonathan A. ;

Hanauer, Stephen B. ;

Loftus, Edward V., Jr. ;

Faubion, William A. ;

Pardi, Darrell S. ;

Tremaine, William J. ;

Kane, Sunanda V. ;

Bruining, David H. ;

Cohen, Russell D. ;

Rubin, David T. ;

Hanson, Karen A. ;

Sandborn, William J. .

INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) :1302-1307

[2]

Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding [J].

Angelberger, Sieglinde ;

Reinisch, Walter ;

Messerschmidt, Agnes ;

Miehsler, Wolfgang ;

Novacek, Gottfried ;

Vogelsang, Harald ;

Dejaco, Clemens .

JOURNAL OF CROHNS & COLITIS, 2011, 5 (02) :95-100

[3]

[Anonymous], UPD TYS PML

[4]

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[5]

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease [J].

Baert, Filip ;

Moortgat, Liesbeth ;

Van Assche, Gert ;

Caenepeel, Philip ;

Vergauwe, Philippe ;

De Vos, Martine ;

Stokkers, Pieter ;

Hommes, Daniel ;

Rutgeerts, Paul ;

Vermeire, Severine ;

D'Haens, Geert .

GASTROENTEROLOGY, 2010, 138 (02) :463-468

[6]

Prospective Randomized Open-label Multicenter Phase I/II Dose Escalation Trial of Visilizumab (HuM291) in Severe Steroid-refractory Ulcerative Colitis [J].

Baumgart, Daniel C. ;

Targan, Stephan R. ;

Dignass, Axel U. ;

Mayer, Lloyd ;

van Assche, Gert ;

Hommes, Daan W. ;

Hanauer, Stephen B. ;

Mahadevan, Uma ;

Reinisch, Walter ;

Plevy, Scott E. ;

Salzberg, Bruce A. ;

Buchman, Alan L. ;

Mechkov, Grigor M. ;

Krastev, Zahariy A. ;

Lowder, James N. ;

Frankel, Matthew B. ;

Sandborn, William J. .

INFLAMMATORY BOWEL DISEASES, 2010, 16 (04) :620-629

[7]

Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO

[8]

2-Z

[9]

TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION [J].

BRAEGGER, CP ;

NICHOLLS, S ;

MURCH, SH ;

STEPHENS, S ;

MACDONALD, TT .

LANCET, 1992, 339 (8785) :89-91

[10]

TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].

BREESE, EJ ;

MICHIE, CA ;

NICHOLLS, SW ;

MURCH, SH ;

WILLIAMS, CB ;

DOMIZIO, P ;

WALKERSMITH, JA ;

MACDONALD, TT .

GASTROENTEROLOGY, 1994, 106 (06) :1455-1466

← 1 2 3 4 5 6 7 8 9 10 →